Skip to content

Tremor, Chorea, and Other Movement Disorders

Chapter 447 | Part 13: Neurologic Disorders

KEY CLINICAL POINTS

  • Hyperkinetic movement disorders include tremor, dystonia, chorea, myoclonus, and tics, characterized by involuntary, rhythmic, or stereotyped movements.
  • Essential tremor (ET) is the most common movement disorder, affecting ~1% of the population, with a high-frequency (6–10 Hz) tremor primarily in the upper extremities.
  • Dystonia is a movement disorder with sustained muscle contractions causing abnormal postures, often with a genetic basis (e.g., DYT1, DYT6, DYT11 mutations).
  • Huntington’s disease (HD) is an autosomal dominant disorder caused by CAG repeat expansion in the HTT gene, leading to chorea, cognitive decline, and psychiatric symptoms.
  • Drug-induced movement disorders (e.g., neuroleptic-induced tardive dyskinesia, akathisia) are common with dopamine-blocking agents and require careful management.

1. DEFINITION & OVERVIEW

Hyperkinetic movement disorders are characterized by involuntary, rhythmic, or stereotyped movements unaccompanied by weakness. These include tremor, dystonia, chorea, myoc, and tics. The term is somewhat arbitrary, as hypokinetic disorders like Parkinson’s disease may also present with tremor. The distinction is based on clinical features, etiology, and pathophysiology.

Table 447-1 Hyperkinetic Movement Disorders

Tremor Dystonia Athetosis Chorea Myoclonus Tic
Rhythmic oscillation of a body part due to intermittent muscle contractions Involuntary, patterned, sustained, or repeated muscle contractions often associated with twisting movements and abnormal posture Slow, distal, writhing, involuntary movements with a propensity to affect the arms and hands Rapid, semi-purposeful, graceful, dance-like nonpatterned involuntary movements Sudden, brief (<100 ms), jerk-like, arrhythmic muscle twitches Brief, repeated, stereotyped muscle contractions that can often be suppressed for a short time

1.1 Hyperkinetic Movement Disorders

Tremor: Involuntary, rhythmic oscillation of a body part due to intermittent muscle contractions. Dystonia: Involuntary, patterned muscle contractions causing abnormal postures. Chorea: Rapid, nonpatterned involuntary movements. Myoclonus: Sudden, brief muscle twitches. Tics: Brief, stereotyped muscle contractions.

1.2 Clinical Classification

Classified along two axes: Axis 1 (clinical characteristics: age of onset, distribution, activation condition) and Axis 2 (etiology: genetic, secondary, idiopathic).

2. EPIDEMIOLOGY

Essential tremor (ET) affects ~1% of the population and 5% of those over 60 years. Dystonia has an estimated prevalence of 30 per 100,000. Huntington’s disease (HD) has a prevalence of 2–8 per 100,000, with an average age at death of 60 years. Drug-induced movement disorders are common with neuroleptic use.

2.1 Risk Factors

Family history (e.g., ET, DYT1 dystonia), age (ET peaks >70 years), gender (ET more common in women), and drug exposure (neuroleptics, levodopa).

2.2 Demographics

ET is more common in women; dystonia has a bimodal age of onset (childhood/adolescence and late adulthood). HD typically presents between 25–45 years.

3. ETIOLOGY & PATHOPHYSIOLOGY

ET is likely polygenic with genetic modifiers, while dystonia has monogenic causes (e.g., DYT1, DYT6). Huntington’s disease is caused by CAG repeat expansion in HTT. Drug-induced disorders result from dopamine receptor blockade or serotonin syndrome.

Table 447-2 Monogenic Forms of Isolated and Combined Dystonia

FORM OF DYSTONIA GENE DESIGNATION AND PHENOTYPIC SUBGROUP ADDITIONAL DISTINGUISHING FEATURES MODE OF INHERITANCE
Isolateda TOR1A DYT-TOR1A Childhood or adolescent onset, generalized AD
Isolateda KMT2B DYT-KMT2B Early onset, generalized, mild syndromic features AD
Isolateda THAP1 DYT-THAP1 Adolescent onset, cranial or generalized AD
Isolateda ANO3 DYT-ANO3 Adult onset, focal or segmental AD
Isolateda GNAL DYT-GNAL Mostly adult onset, focal or segmental AD
Isolateda VPS16 DYT-VPS16 Frequent cervical and laryngeal dystonia AD or AR
Combinedb GCH1 DYT-GCH1 Dopa-responsive AD
Combinedb TAF1 DYT-TAF1 Neurodegeneration XL
Combinedb ATP1A3 DYT-ATP1A3 Rapid onset AD
Combinedb SGCE DYT-SGCE Alcohol responsive AD

3.1 Genetic Basis

ET: ~50% familial, autosomal dominant. Dystonia: Monogenic (e.g., DYT1, DYT6, DYT11) or secondary (e.g., Wilson’s disease, stroke). HD: Autosomal dominant CAG repeat expansion in HTT.

3.2 Pathophysiology

ET: Altered cerebellar function and GABAergic pathways. Dystonia: Basal ganglia dysfunction, loss of surround inhibition, and abnormal motor circuitry. HD: Neurodegeneration of striatum and cortex due to mutant HTT.

4. CLINICAL FEATURES

Tremor: High-frequency (6–10 Hz), postural/action tremor. Dystonia: Sustained muscle contractions causing abnormal postures. Chorea: Rapid, nonpatterned movements. Myoclonus: Sudden jerks. Tics: Stereotyped movements. HD: Chorea, cognitive decline, psychiatric symptoms.

4.1 Tremor

Defined as involuntary, rhythmic oscillation of a body part. Most common in upper extremities, worsened by stress. Improved by alcohol. May be physiological or pathological.

4.2 Dystonia

Sustained muscle contractions causing twisting movements and abnormal postures. May involve focal (e.g., cervical dystonia), segmental, or generalized patterns.

4.3 Chorea

Rapid, nonpatterned involuntary movements. In HD, chorea is often accompanied by cognitive and psychiatric features. Sydenham’s chorea is associated with streptococcal infection.

5. DIFFERENTIAL DIAGNOSIS

Distinguish ET from PD (rest tremor vs. action tremor), dystonia from chorea, and drug-induced movement disorders from primary disorders. Consider Wilson’s disease, Huntington’s disease, and paroxysmal dyskinesias.

5.1 Essential Tremor vs. Parkinson’s Disease

ET: Action/postural tremor, improved by alcohol. PD: Rest tremor, bradykinesia, rigidity. ET is more common in older adults.

5.2 Dystonia vs. Chorea

Dystonia: Sustained muscle contractions. Chorea: Rapid, nonpatterned movements. Dystonia may be focal (e.g., cervical dystonia) or generalized.

6. INVESTIGATIONS & DIAGNOSIS

MRI for structural abnormalities (e.g., basal ganglia lesions), genetic testing for monogenic disorders (e.g., DYT1, HTT), and metabolic studies (e.g., ceruloplasmin for Wilson’s disease).

6.1 Diagnostic Criteria

ET: Family history, high-frequency tremor. Dystonia: Genetic testing for DYT mutations. HD: CAG repeat expansion in HTT. Drug-induced: History of neuroleptic use.

6.2 Imaging

MRI for basal ganglia abnormalities (e.g., HD, Wilson’s disease). Functional imaging (e.g., PET) for dopamine transporter studies in PD.

7. MANAGEMENT & TREATMENT

Pharmacologic: Beta-blockers (propranolol), primidone, dopamine agonists. Surgical: DBS for dystonia, thalamotomy. Non-pharmacologic: Physical therapy, botulinum toxin for focal dystonia.

Table 447-3 Drug Treatment for Movement Disorders

Disorder Drug Dose Comments
Essential Tremor Propranolol 20–120 mg/d Effective for action tremor
Essential Tremor Primidone 12.5–250 mg three times daily Sedation, nausea
Dystonia Tetrabenazine 12.5–75 mg/d Parkinsonism risk
Dystonia Baclofen 20–120 mg/d Intrathecal for severe cases
Huntington’s Disease Tetrabenazine 12.5–75 mg/d Dopa-responsive
Tics Clonidine 0.15–0.5 mg/d a-agonist for TS

7.1 Pharmacologic Therapy

ET: Propranolol (20–120 mg/d), primidone (12.5–250 mg three times daily). Dystonia: Tetrabenazine, deutetrabenazine, baclofen. HD: Tetrabenazine, valbenazine.

7.2 Surgical Options

DBS of globus pallidus internus for generalized dystonia. Thalamotomy for tremor. Pallidotomy for hemiballismus.

8. PROGNOSIS & COMPLICATIONS

ET is generally benign but may progress with age. Dystonia can be disabling with severe motor complications. HD is progressive and fatal, with average survival of 15–20 years. Drug-induced disorders may persist or become permanent.

8.1 Complications

Dystonia: Severe disability, muscle contractures. HD: Cognitive decline, psychiatric symptoms. Drug-induced: Tardive dyskinesia, akathisia.

8.2 Prognosis

ET: Generally stable. Dystonia: Variable, with some forms responsive to DBS. HD: Progressive, fatal. Drug-induced: Often reversible with drug withdrawal.

9. SPECIAL CONSIDERATIONS

Pregnancy: Avoid neuroleptics. Pediatrics: Dystonia may be familial (e.g., DYT1). Elderly: Higher risk of drug-induced movement disorders. Wilson’s disease: Copper metabolism disorder with KF rings.

9.1 Pregnancy

Avoid neuroleptics (e.g., haloperidol) due to risk of dystonia. Monitor for drug-induced movement disorders.

9.2 Pediatrics

Focal dystonia (e.g., writer’s cramp) may be familial. Early-onset dystonia (e.g., DYT1) requires genetic testing.

10. KEY POINTS & CLINICAL PEARLS

  1. Essential tremor is the most common movement disorder, with a high-frequency tremor. 2. Dystonia has a strong genetic basis (e.g., DYT1, DYT6). 3. Huntington’s disease is caused by CAG repeat expansion in HTT. 4. Drug-induced movement disorders (e.g., tardive dyskinesia) require careful management. 5. DBS is effective for severe dystonia and chorea.